Abstract：
OBJECTIVE: The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life.
METHODS: We conducted a retrospective observational study of patients with Parkinson\'s disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs.
RESULTS: Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years±8.43 and H&Y stage was 3 [2-4]. Mean dose of levodopa used was 703.75mg±233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation.
CONCLUSIONS: Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.
METHODS: We conducted a retrospective observational study of patients with Parkinson\'s disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs.
RESULTS: Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years±8.43 and H&Y stage was 3 [2-4]. Mean dose of levodopa used was 703.75mg±233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation.
CONCLUSIONS: Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.
摘要：
目的：本研究的目的是评估沙芬酰胺和抗抑郁药之间可能的药理相互作用，特别是5-羟色胺综合征的出现和来自现实生活的数据。
方法：我们对运动障碍科的帕金森病患者进行了一项回顾性观察研究，他们正在接受任何抗抑郁药物和沙芬酰胺的治疗。具体来说,筛查提示5-羟色胺综合征的症状.此外，我们收集了同时使用的时间，左旋多巴和其他抗帕金森病药物的剂量。
结果：回顾了2018年9月至2019年9月研究期间的临床记录。78例接受safinamide治疗的PD患者，其中25例（32.05％）同时接受抗抑郁药治疗，最常见的是舍曲林和艾司西酞普兰。平均年龄为80岁±8.43，H&Y分期为3[2-4]。使用的左旋多巴的平均剂量为703.75mg±233.15。沙芬酰胺和抗抑郁药物联合治疗的中位持续时间为6个月（IQR20.5），5例超过18个月。无血清素综合征病例记录，它的任何典型表现都没有结合或孤立。
结论：我们的实际临床实践研究表明，在PD患者中同时使用safinamide与抗抑郁药物似乎是安全且耐受性良好的，即使是长期的。然而,谨慎是必要的，个体化治疗方案并监测潜在的不良反应。
方法：我们对运动障碍科的帕金森病患者进行了一项回顾性观察研究，他们正在接受任何抗抑郁药物和沙芬酰胺的治疗。具体来说,筛查提示5-羟色胺综合征的症状.此外，我们收集了同时使用的时间，左旋多巴和其他抗帕金森病药物的剂量。
结果：回顾了2018年9月至2019年9月研究期间的临床记录。78例接受safinamide治疗的PD患者，其中25例（32.05％）同时接受抗抑郁药治疗，最常见的是舍曲林和艾司西酞普兰。平均年龄为80岁±8.43，H&Y分期为3[2-4]。使用的左旋多巴的平均剂量为703.75mg±233.15。沙芬酰胺和抗抑郁药物联合治疗的中位持续时间为6个月（IQR20.5），5例超过18个月。无血清素综合征病例记录，它的任何典型表现都没有结合或孤立。
结论：我们的实际临床实践研究表明，在PD患者中同时使用safinamide与抗抑郁药物似乎是安全且耐受性良好的，即使是长期的。然而,谨慎是必要的，个体化治疗方案并监测潜在的不良反应。
